Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nevirapine resistance after single dose prophylaxis.

AIDS reviews - 1 Jan 2000

Eshleman Susan H, Jackson J Brooks

Abstract excerpt

Nevirapine (NVP) is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase. In 1999, the HIVNET 012 trial in Uganda demonstrated that a simple regimen of NVP prophylaxis can dramatically reduce the rate of HIV-1 mother-to-child transmission (MTCT). In the HIVNET 012 regimen, women received a single dose of NVP in labor, and infants received a single dose of NVP within 72 h of birth. The simplicity,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4 Lymphocyte Count
Share to Drug Resistance, Viral
Share to Infectious Disease Transmission, Vertical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nevirapine

Share to Pregnancy Complications, Infectious

Share to Reverse Transcriptase Inhibitors

Share to Uganda

Share to Viral Load

Source

Identifiers

PMID: 12152519

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nevirapine resistance after single dose prophylaxis.PMID 12152519Read ↗

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).Semantic proximity Read ↗

Emergence and Persistence of Minor Drug-Resistant HIV-1 Variants in Ugandan Women after Nevirapine Single-Dose ProphylaxisSemantic proximity Read ↗

Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.Semantic proximity Read ↗

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.Semantic proximity Read ↗

Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.Semantic proximity Read ↗

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.Semantic proximity Read ↗

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).Semantic proximity Read ↗

Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.Semantic proximity Read ↗

Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype A vs. D After Single-Dose NevirapineSemantic proximity Read ↗

Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.Semantic proximity Read ↗

Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.Semantic proximity Read ↗

Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.